Merck & Co., Inc. (MRK.MX)
| Previous close | 2,227.52 |
| Open | 2,252.70 |
| Bid | 1,770.00 x 49400 |
| Ask | 2,299.00 x 13500 |
| Day's range | 2,252.70 - 2,252.70 |
| 52-week range | 1,725.90 - 2,252.70 |
| Volume | |
| Avg. volume | 1,863 |
| Market cap | 5.719T |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.96 |
| EPS (TTM) | 15.54 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 51.09 (2.27%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
Simply Wall St.Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
BenzingaMerck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
ZacksMerck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
